At ECR 2026, PreciseOnco brought together leading experts in interventional radiology and interventional oncology to discuss how innovation, collaboration, and data-driven technologies are transforming cancer care.
In this interview, Atul Gupta, MD, representing Philips, and Jean-Baptiste Pialat, from Hospices Civils de Lyon (HCL), shared their perspectives on the growing importance of precision medicine and image-guided therapies in oncology.
The Evolving Role of Interventional Oncology
Interventional radiology is the fourth pillar of modern cancer care, providing minimally invasive treatment options that can target tumors with high precision while minimizing the impact on healthy tissues. As treatment pathways become increasingly personalized, healthcare teams require advanced tools that support clinical decision-making, treatment planning, and outcome assessment.
The discussion highlights how innovations in imaging, data integration, and procedural guidance are helping clinicians deliver more precise and efficient care throughout the patient journey.
Why PreciseOnco Matters
PreciseOnco was developed with a clear objective: to support healthcare professionals in optimizing interventional oncology workflows and improving the quality of care delivered to patients.
During the interview, the speakers emphasize how the project contributes to:
- Enhancing treatment precision through advanced imaging capabilities
- Supporting data-driven clinical decisions
- Streamlining workflows for multidisciplinary care teams
- Facilitating collaboration between specialists
- Enabling a more personalized approach to cancer treatment
These capabilities help physicians better understand treatment outcomes and continuously improve patient care strategies.
Generating Evidence Through the LASER Study
A key example of PreciseOnco’s impact is its support of the LASER study, a multicenter initiative designed to generate real-world evidence in interventional oncology. The study focuses on collecting and analyzing clinical and imaging data to better understand treatment effectiveness and patient outcomes following minimally invasive cancer therapies.
By standardizing data collection and facilitating collaboration across institutions, the LASER study helps clinicians gain valuable insights into treatment response, procedural performance, and long-term outcomes. Such evidence is essential for advancing best practices, supporting clinical decision-making, and demonstrating the value of innovative interventional oncology approaches.
